GALT
Galectin TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
FDA alignment materially improves regulatory clarity, while NAVIGATE biomarker and liver-stiffness analyses provide supportive signals for belapectin. The Q3 2026 Phase 3 protocol submission could create a clearer development path.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
FDA agreement on the regulatory framework does not guarantee clinical success or approval.
Momentum
99
Value
41
Sentiment
89
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.25 · Bull $11.00 · Bear $2.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum99 · Δ7d -
Value41 · Δ7d -0.1
Sentiment89 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
89
34% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.8 / Value 41.1 / Sentiment 88.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$274.95M
Beta
1.01
Shares Out
65.86M
P/E (TTM) · Derived
-8.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.44
Rev YoY
-
EPS YoY
-49.3%
Gross Margin
-
Op Margin
-
Net Debt
$116.04M
Current Ratio
2.15
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology